Results from a 10,000-string trial shows the duo’s COVID-19 vaccine shows full restoration of protection.
Earlier today, the duo announced that a booster shot of their COVID-19 vaccine restored full protection to participants in a large Phase III trial. Results from the study showed a booster shot was 95.6% effective against symptomatic COVID-19 in people 16 and older, and are seen as a major boost in favour of a third dose. “We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,” Pfizer Chief Executive Officer Albert Bourla. “These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” added Bourla. The trial evaluated the efficacy and safety of a 30-µg booster dose of the vaccine in 10,000 participants who had previously received the two-dose regimen of the vaccine.
Pfizer’s vaccine has dominated the booster shot debate across the globe. Last month, the FDA cleared the vaccine as a booster for those aged 65 years and older, those aged between and 64 who are at high risk of severe COVID-19, as well as those aged between 18 and 64 with frequent institutional or occupational exposure to SARS-CoV-2. Just yesterday, “a booster dose of the vaccine also was authorized for emergency use by the FDA in eligible individuals who have completed a primary vaccination with a different authorized COVID-19 vaccine,” read the statement published on Pfizer’s website. Furthermore, the vaccine also got a nod to be used as a booster shot across the EU and other countries, though with varying recommendations for populations wherein this would be suitable.